SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a major trending topic as its Q4 earnings, which beat expectations, were met with a significant stock dip, fueling intense debate among investors. The community is sharply divided, with many viewing the sharp decline as a prime 'buy the dip' opportunity for a long-term hold, citing strong fundamentals. Conversely, bears are expressing concerns over cautious guidance, the implications of its Warner Bros. Discovery acquisition, increased content spending, and the pausing of share buybacks.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is a hot topic as the community anticipates significant announcements, fueled by recent industry awards and confirmation of continued work with Celestial AI, now part of Marvell. Discussion centers on POET's patented optical interposer technology, seen as a crucial solution for the escalating demand for high-speed, power-efficient optical interconnects in AI data centers. Many believe the company is poised for major customer orders, positioning it as a key player in the ongoing optical supercycle.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending as gold surges, fueled by escalating geopolitical tensions, including discussions around Trump's tariff threats against European nations and the Greenland issue. The community is actively debating if this signifies a sustained shift towards real assets due to eroding trust in fiat currencies, or if it's a momentum-driven rally susceptible to de-escalation.

America's Oil Reserve for the Digital Age

U.S Oil

USOR CRYPTO is experiencing a highly polarized trend following a rapid price surge, sparking intense community debate. While many celebrate substantial gains and anticipate further rallies, a vocal segment warns of a potential "rug pull" or pump-and-dump, cautioning investors due to its meme coin characteristics. Amidst this volatility, new participants are actively seeking information on how to acquire the token.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is actively discussed amid its upcoming separation into two independent companies and the appointment of a new CEO, with many anticipating this will unlock significant value. Community sentiment is polarized between those who see current price levels as a rare buying opportunity and those concerned about it being a "value trap," often fueled by claims of market manipulation and recent analyst downgrades.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust (SPY) is actively trending amid heightened geopolitical rhetoric, particularly surrounding discussions of a potential U.S. acquisition of Greenland and associated tariff implications. The community is sharply divided, with many anticipating a significant rebound from a recent market dip, while others express concerns about escalating global tensions and upcoming public statements from a prominent political figure. Broader market sentiment is currently influenced by a tug-of-war between 'buy the dip' enthusiasm and fears of further instability affecting international asset holdings.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following significant insider share purchases, including CEO Ryan Cohen's acquisition of 500,000 shares. This has ignited strong bullish sentiment within the community, with many interpreting the buys as a powerful signal of conviction and a potential catalyst for a renewed short squeeze. Investors are actively discussing the company's strong balance sheet and lack of debt, anticipating a major move for the meme stock.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is experiencing significant volatility, with recent analyst downgrades sparking accusations of market manipulation and creating confusion among investors despite the company's strong AI server demand and increased revenue guidance. While many in the community view the recent price dip as a prime buying opportunity given its low valuation and record AI server backlog, others remain cautious amid concerns over memory price inflation and competitive pressures in the AI infrastructure market.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF (DIA) is trending due to renewed tariff threats from a US political figure concerning an international territory, fueling global trade war fears. This has sparked widespread community discussion, with many anticipating significant market volatility and potential capital flight, while others remain optimistic about a swift market rebound amid broader geopolitical tensions.

Virtu Financial, Inc. engages in the provision of trading solutions and liquidity services. It operates through the following segments: Market Making, Execution Services, and Corporate. The Market Making segment involves the cash, futures, and options markets across global equities, fixed income, currencies, cryptocurrencies, and commodities. The Execution Services segment includes agency-based, execution-only trading, workflow technology, and trading analytics. The Corporate segment consists of investments in financial services-oriented opportunities and maintains corporate overhead expenses and all other income and expenses that are not attributable to the other segments. The company was founded by Vincent J. Viola and Douglas A. Cifu in 2008 and is headquartered in New York, NY.

Virtu Financial Inc - Ordinary Shares - Class A

Virtu Financial is trending due to robust earnings reports that have consistently exceeded expectations, fueled by sustained market volatility and high trading volumes, including growing crypto market participation. While many are optimistic about its market-making operations, a vocal community segment remains critical, often linking the company to allegations of market manipulation and ongoing lawsuits. This dual narrative highlights intense, contrasting discussions surrounding its operational success and perceived controversies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Ocular Therapeutix had reportedly rejected Sanofi’s initial takeover bid in September.</li><li>If the acquisition goes through, it would bolster Sanofi’s footprint in ophthalmology.</li><li>Sanofi recently acquired Dynavax to boost its vaccine portfolio.</li></ul>Ocular Therapeutix (OCUL) was back on retail’s radar, with the stock surging 13% in premarket trading on Thursday, after reports emerged that French pharmaceutical giant Sanofi (SNY) is preparing an offer to acquire the American biopharmaceutical firm.According to French publication La Lettre, the renewed interest comes after Ocular Therapeutix rejected Sanofi’s initial takeover bid in September, when the group offered $16 per share, a substantial premium to Ocular’s then-trading price of about $10.50.<a href="https://stocktwits.com/symbol/OCUL">OCUL shares</a> have been on a downtrend lately, declining in 11 of the last 13 sessions. <a href="https://stocktwits.com/symbol/SNY">SNY stock</a> was down 0.4% in pre-open trade.<h2 class="st-heading-2">Acquisition Rationale</h2>If the acquisition goes through, it would bolster Sanofi’s footprint in ophthalmology, particularly in age-related macular degeneration, which affects the central part of the retina.At the same time, it could support Sanofi’s push into combination therapies, with Ocular’s treatments, such as Dextenza for ocular inflammation, potentially pairing well with existing drugs like Dupixent, given studies suggesting links between chronic skin conditions and eye disorders such as cataracts.<h2 class="st-heading-2">Sanofi’s Acquisition Spree</h2>Sanofi has been ramping up its strategy to add to its portfolio through key acquisitions over the last few months. In late December, Sanofi signed an agreement to acquire vaccine maker Dynavax Technologies Corp (DVAX) in a <a href="https://stocktwits.com/news-articles/markets/equity/why-did-dynavax-stock-surge-38-in-premarket-today/cLesA4mREHU">$2.2 billion deal</a> aimed at strengthening its adult immunization portfolio. The transaction will strengthen Sanofi’s global vaccines business by bringing in Dynavax’s approved adult hepatitis B vaccine, HEPLISAV-B, along with a differentiated shingles vaccine.In June, Sanofi agreed to <a href="https://stocktwits.com/news-articles/markets/equity/sanofi-to-buy-blueprint-medicines-for-up-to-9.5-billion/chkoCYnRbHc">acquire Blueprint</a> Medicines for about $9.1 billion to deepen its presence in the cure for rare immunological diseases. The acquisition added Ayvakit/Ayvakyit, the only approved treatment for systemic mastocytosis, along with pipeline assets including Elenestinib and BLU-808 to Sanofi’s portfolio.<h2 class="st-heading-2">How Did Retail React?</h2>Retail sentiment for OCUL on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, accompanied by ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/OCUL_jpg_9ede93e8cf.webp" alt="OCUL.jpg" width="928" height="100"><figcaption>OCUL's Sentiment Meter and Message Volumes at Premarket on Jan. 15, 2026 | Source: Stocktwits</figcaption></figure>One user sees upside in OCUL stock due to the offer.<stembedurl>https://stocktwits.com/scholar9/message/641880419</stembedurl>OCUL shares have gained around 34% over the past year.Read also: <a href="https://stocktwits.com/news-articles/equity/markets/nasdaq-sp500-futures-pause-nvda-tsm-msft-cvx-stocks-to-watch/cmU1L2fR47N">Nasdaq, S&amp;P 500 Futures Pause Ahead Of Major Bank Earnings, Jobless Claims: Why NVDA, TSM, CVX, MSFT, AMZN Are On Traders' Radar Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did OCUL Stock Jump 13% In Pre-Market Today?

French pharmaceutical giant Sanofi is preparing an offer to acquire the American biopharmaceutical firm, according to a report by French publication La Lettre.

OCUL Stock Back On Retail Radar With Sanofi Takeover Speculation Resurfacing

Equity

<ul class="summary-bullets"><li>flyExclusive will begin installing Starlink on its fleet to provide high-speed, low-latency internet connection at high altitudes.&nbsp;</li><li>The company will also provide sales, installation, and support services to third-party aircraft owners and operators.&nbsp;</li><li>Starlink installations on flyExclusive’s Challenger 350 fleet will begin in early 2026.</li></ul>flyExclusive, Inc. (FLYX) shares more than doubled on Thursday after the private jet operator announced an authorized dealership agreement with SpaceX’s Starlink.As per the agreement, flyExclusive said it will begin installing Starlink on its fleet to provide high-speed, low-latency internet connection at high altitudes.The aviation company said that installations on its Challenger 350 fleet will kick off in early 2026.Shares of FLYX rallied over 130% at the time of writing.<h2 class="st-heading-2">The Starlink Deal</h2>Apart from providing Starlink connectivity on its own jets, flyExclusive will also provide sales, installation, and support services to third-party aircraft owners and operators. The company said that the move expands its Maintenance, Repair, and Operations (MRO) capabilities.flyExclusive’s deal with Starlink is aimed at improving streaming quality, real-time communications, and consistent VPN performance at high altitudes on all its jets.Starlink’s 310 Mbps connectivity with low latency will support HD video conferencing, streaming, large file transfers, and modern productivity tools on flights.The Starlink dealership aligns with the company’s technology investment, customer experience, and fleet modernization plans, the company said.“Connectivity is no longer a luxury. It is a core part of the passenger experience,” said Matt Lesmeister, Chief Operating Officer of flyExclusive. “Becoming a Starlink aviation dealer strengthens our MRO capabilities while raising the bar across our fleet.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/FLYX">FLYX shares</a> jumped to ‘extremely bullish’ from ‘bullish’ sentiment a day ago as message volumes spiked to ‘extremely high’.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_08_at_9_39_06_PM_png_6f11fe3664.webp" alt="On Stocktwits, retail sentiment around FLYX shares jumped to ‘extremely bullish’ from ‘bullish’ sentiment a day ago as message volumes spiked to ‘extremely high’." width="1285" height="148"></figure>&nbsp;One bullish user praised the deal, saying the stock could jump to $9.00 levels by the end of the trading session. Shares of FLYX traded around $7.28 at the time of writing.<stembedurl>https://stocktwits.com/come_litaliano/message/641194617</stembedurl>&nbsp;FLYX stock has climbed over 120% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-crmd-stock-crash-28-today/cmUbayOR45b">Why Did CRMD Stock Crash 28% Today?</a> &nbsp;

A SpaceX Falcon 9 rocket carrying a payload of 24 Starlink internet satellites soars into space after launching from Vandenberg Space Force Base on July 18, 2025, seen from Santee, California.

FLYX Stock Surged Over 130% Today — What’s The SpaceX Connection?

Private jet operator flyExclusive announced an authorized dealership agreement with SpaceX’s Starlink on Thursday.

FLYX Stock Surges 130% — What’s The SpaceX Connection?

Private jet operator flyExclusive announced an authorized dealership agreement with SpaceX’s Starlink on Thursday. 

<ul class="summary-bullets"><li>For Tether, the launch represents the first real-world deployment of its WDK, designed to help platforms roll out wallets without centralized custodians.</li><li>MoonPay, a crypto payments company,&nbsp;will support on- and off-ramps, allowing users to move between crypto and traditional payment methods.</li><li>The goal for Rumble is to cut out intermediaries such as banks, ad networks, and payment processors.</li></ul>Rumble Inc. (RUM) shares rose over 4% on Wednesday after the company partnered with Tether to launch Rumble Wallet, a non-custodial crypto wallet that integrates digital asset payments directly into its video-sharing platform.At present, the wallet supports Bitcoin, Tether (USDT), and Tether Gold (XAUt). By integrating crypto payments at the platform level, Rumble aims to cut out intermediaries such as banks, ad networks, and payment processors. The Rumble Wallet is built using Tether’s Wallet Development Kit (WDK).For Tether, the launch represents the first real-world deployment of its WDK, designed to help platforms roll out wallets without centralized custodians.&nbsp;Crypto payments company, MoonPay, will support on- and off-ramps, allowing users to move between crypto and traditional payment methods, including credit cards, Apple Pay, PayPal, and Venmo.“Peer-to-peer payments powered by crypto are the future of the internet economy. Rumble is one of the first major platforms to adopt this model, giving creators the ability to get paid instantly in stablecoins or Bitcoin and easily move in and out of fiat,” said Ivan Soto-Wright, CEO of MoonPay.<h2 class="st-heading-2">Rumble’s Growth Strategy</h2>The wallet launch comes as Rumble, a video streaming and cloud company that hosts U.S. President Donald Trump’s Truth Social platform, advances its broader growth strategy. The company recently confirmed it filed an S-4 with U.S. regulators for its proposed $767 million all-stock merger with German data center operator Northern Data, a deal first announced in November.If completed, the transaction would transform Rumble into a full-stack cloud services provider with a sizable data center footprint across the U.S. and Europe and access to more than 22,000 Nvidia GPUs. Tether has also committed to a $150 million GPU leasing agreement with the combined entity, positioning Rumble to benefit from surging demand for AI-focused data center infrastructure.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘high’ message volumes. <a href="https://stocktwits.com/symbol/RUM">RUM</a> was among the top trending stocks at the time of writing.<img src="https://news.stocktwits-cdn.com/RUM_jpg_b24d50a5b1.webp" alt="RUM.jpg">One user expects the stock to climb over $10. It is currently trading near $7.<stembedurl>https://stocktwits.com/Nopainnogain99/message/641062575</stembedurl>Over the past year, the stock has declined nearly 50%.Read Also: <a href="https://stocktwits.com/news-articles/markets/equity/alaska-airlines-places-record-order-for-boeing-737-10-787-jets/cmxzcYDR429">Alaska Airlines Places Record Order for Boeing 737-10, 787 Jets</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 2025/02/03: In this photo illustration, the Rumble logo is seen displayed on a smartphone screen.

Rumble Rallies After Unveiling Tether-Powered Crypto Wallet – Retail Expects Stock To Surpass The $10 Mark

The wallet, built with Tether’s Wallet Development Kit, currently supports Bitcoin, Tether (USDT), and Tether Gold (XAUt).

Zeta Global, an AI marketing firm, said on Monday it has entered into a strategic collaboration with OpenAI to integrate its advanced AI models into its marketing platform named Athena, sending shares of Zeta Global soaring 9% in after-market trading.&nbsp;Zeta will also have the opportunity for early access to new OpenAI models and features, enabling deeper integration with the latest advancements in AI, it said.&nbsp;The companies will align Athena's product roadmap with advances in OpenAI models, accelerating how enterprise teams get decision-ready answers inside their daily workflows, it stated.&nbsp;<h2 class="st-heading-2">Athena Platform</h2>Zeta’ Athena platform personalizes marketers’ workspaces with voice-activated answers. It allows marketers at the platform to interact with data and automate their tasks. Zeta unveiled its Athena platform in October last year.&nbsp;Zeta plans to launch Athena to all customers by the end of the first quarter of (Q1) 2026.“Zeta shows how advanced AI moves beyond insight and into action,” said Giancarlo ‘GC’ Lionetti, Chief Commercial Officer at OpenAI. “By working together, we are bringing agentic intelligence directly into everyday marketing workflows, helping enterprises move faster and act with confidence.”TKO Group Holdings, Inc., the premium sports and entertainment company that comprises UFC and WWE, was part of Athena's Early Access Program.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around ZETA trended in ‘extremely bullish’ territory amid ‘high’ message volumes.&nbsp;One bullish user predicted stock to hit $30 on Tuesday.&nbsp;<stembedurl>https://stocktwits.com/Tetsuo_shima/message/640886808</stembedurl>Zeta will also have the opportunity for early access to new OpenAI models and features, enabling deeper integration with the latest advancements in AI, it said.&nbsp;The companies will align Athena's product roadmap with advances in OpenAI models, it added.&nbsp;Get updates to this developing story directly on Stocktwits. &nbsp;

In this photo illustration, a person holds a smartphone displaying the logo of Zeta Global Holdings Corp. 

Zeta Global Shares Rose After It Deepens Collaboration with OpenAI 

Zeta will also have the opportunity for early access to new OpenAI models and features, enabling deeper integration with the latest advancements in AI. 

<ul class="summary-bullets"><li>The outlook assumes net sales for Linzess will be between $1.125 billion and $1.175 billion in FY2026.</li><li>U.S. FDA had approved Ironwood’s Linzess capsules for pediatric patients, in November.</li><li>Linzess is the first treatment approved for the irritable bowel syndrome with constipation in pediatric patients.</li></ul>Shares of Ironwood Pharmaceuticals (<a href="https://stocktwits.com/symbol/IRWD">IRWD</a>) jumped more than 38% in premarket trading on Friday after its FY2026 guidance came in above expectations, boosted by higher sales of its drug Linzess, which is used to treat constipation.The biotechnology company said it expects FY2026 revenue in the range of $450 million to $475 million, higher than analyst expectations of $319.5 million, according to data from Fiscal.ai.&nbsp;The outlook assumes net sales of Linzess will be between $1.125 billion and $1.175 billion in FY2026, driven by improved net price and low-single-digit demand growth, the company said.&nbsp;“We believe our full-year 2026 guidance demonstrates the significant progress we’ve made to deliver on these priorities to help drive value for shareholders moving forward,” it stated.&nbsp;<h2 class="st-heading-2">Linzess’ Potential</h2>In November, the U.S. Food and Drug Administration approved Ironwood’s Linzess capsules for pediatric patients aged seven and older with irritable bowel syndrome with constipation.Linzess is the first treatment approved for the disease in pediatric patients, the FDA had said at the time. Irritable bowel syndrome with constipation (IBS-C) is a common functional gastrointestinal disorder characterized by recurrent abdominal pain associated with infrequent, hard-to-pass stools. The contributing factors to the condition are typically multiple.Linzess is already approved for the treatment of adult patients with the condition. The FDA had noted that the safety and efficacy of Linzess were similar in clinical studies for both adults and pediatric patients.“Throughout 2025, we made significant progress in maximizing LINZESS while delivering sustained profits and cash flows in an effort to strengthen our financial position and maintain compliance with debt covenants over the coming quarters,” said Tom McCourt, chief executive officer of Ironwood. “We expect higher net sales in 2026 for LINZESS year-over-year,” he added.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around IRWD trended in ‘bullish’ territory amid ‘high’ message volumes.&nbsp;<figure class="image"><img style="aspect-ratio:632/64;" src="https://news.stocktwits-cdn.com/irwd_2_PNG_f7f4732ebe.webp" alt="Retail sentiment around IRWD trended in ‘bullish’ territory amid ‘high’ message volumes. " width="632" height="64"></figure>One user wondered whether the stock will hit the $10 mark.&nbsp;<figure class="image"><img style="aspect-ratio:667/154;" src="https://news.stocktwits-cdn.com/irwd_PNG_26af83bb21.webp" alt="One user wondered whether the stock will hit the $10 mark. " width="667" height="154"></figure>&nbsp;Shares in the IRWD fell 25.1% in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

The Linzess Room at Ironwood Pharmaceuticals in Cambridge, MA on April 20, 2018. (Photo by Craig F. Walker/The Boston Globe via Getty Images)

Why Did Ironwood Pharmaceuticals Stock Skyrocket Today?

The company announced on Friday that it expects FY2026 revenue in the $450 million to $475 million range. 

<ul class="summary-bullets"><li>While the discontinued trial yielded early and sustained anti-tumor responses, next generation G12C inhibitors are establishing a new benchmark with higher response rates, Verastem CMO said.&nbsp;</li><li>Verastem said it will now focus its resources on the clinical development of VS-7375 in advanced NSCLC and other solid tumors.&nbsp;</li><li>VS-7375 demonstrated a 69% response rate in advanced KRAS G12D NSCLC.</li></ul> Shares of Verastem Oncology (VSTM) fell 2% after hours on Monday after the company said that it has decided to discontinue its trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) following evaluation of interim data.No more patients will be enrolled in the trial being conducted in collaboration with Amgen and those already enrolled can continue treatment as per the investigator's discretion, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251229302295/en/Verastem-Oncology-Provides-Update-on-RAMP-203-Phase-12-Clinical-Trial-for-Advanced-KRAS-G12C-Mutant-Non-Small-Cell-Lung-Cancer">said</a>. The trial was evaluating Avutometinib and Amgen’s Sotorasib in a “doublet combination” and also with Defactinib as a “triplet combination” in patients naïve to or previously treated with a KRAS G12C inhibitor, which is a targeted cancer drug that block the specific KRAS G12C mutation.The company said it is assessing opportunities to share data from the interim analysis in the future. &nbsp;<h2 class="st-heading-2">Fresh Focus</h2>Verastem said it will now focus its resources on the clinical development of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in advanced NSCLC and other solid tumors while also evaluating Avutometinib plus Defactinib in combination with chemotherapy in first line metastatic pancreatic cancer.“While avutometinib plus defactinib combined well with a G12C inhibitor to drive early and sustained anti-tumor responses, next generation G12C inhibitors are establishing a new benchmark with higher response rates,” chief medical officer John Hayslip said.Hayslip added that VS-7375 demonstrated a 69% response rate in advanced KRAS G12D NSCLC.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around VSTM jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours while message volume stayed at ‘low’ levels.A Stocktwits user applauded the decision as “sound.”<stembedurl>https://www.stocktwits.com/Drew613/message/640355285</stembedurl>Another opined that the VS-7375 numbers are “very exciting” and said they could see why the company prioritized it over the discontinued trial.<stembedurl>https://www.stocktwits.com/Sawnchey/message/640352752</stembedurl><a href="https://stocktwits.com/symbol/VSTM">VSTM stock</a> has gained 50% this year and more than doubled over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-supplier-reportedly-slashes-contract-in-part-due-to-lower-than-expected-cybertruck-demand/cL7dT7ARExx">Tesla Supplier Reportedly Slashes Contract In Part Due To Lower-Than-Expected Cybertruck Demand</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Verastem Oncology logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Verastem Oncology Stock Drops After Hours After Discontinuing A Clinical Trial In Lung Cancer

The company discontinued its trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) following evaluation of interim data. 

<ul class="summary-bullets"><li>Afrezza revenue rose 23% to $18.49 million in the three months through the end of September, owing to higher prices and demand.&nbsp;</li><li>Revenue from the V-Go insulin delivery patch, however, slipped 19% to $3.8 million due to low demand.&nbsp;</li><li>MannKind’s adjusted earnings per share came in at $0.07, above an analyst estimate of $0.02, according to data from Fiscal AI.&nbsp; &nbsp;</li></ul>Shares of MannKind Corporation (MNKD) rose 8% on Wednesday after the company reported 17% growth in total revenue to $82.13 million, thanks to significant growth in its Afrezza inhaled insulin sales.Afrezza revenue <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/05/3181424/29517/en/MannKind-Corporation-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html">rose</a> 23% to $18.49 million in the three months through the end of September, owing to higher prices and demand, while royalties rose to $33.32 million. Revenue from the V-Go insulin delivery patch, however, slipped 19% to $3.8 million due to low demand.<h2 class="st-heading-2">Q3 Performance</h2>MannKind’s adjusted earnings per share came in at $0.07, up from $0.06 in the corresponding quarter of 2024, and above an analyst estimate of $0.02, according to data from Fiscal AI.The company ended the quarter with cash, cash equivalents, and investments of $286.3 million, after utilizing approximately $133.2 million and borrowing an additional $250 million to fund the <a href="https://stocktwits.com/news-articles/markets/equity/mannkind-corporation-to-acquire-scpharmaceuticals/chssVp5Rd1m">acquisition</a> of scPharmaceuticals, which was completed in October.The acquisition is expected to accelerate MannKind’s revenue growth with the addition of Furoscix to its portfolio. Furoscix is used to treat fluid overload in adult patients with chronic heart failure (CHF) and chronic kidney disease (CKD).“The acquisition of scPharmaceuticals marks a significant expansion of our commercial capabilities and is expected to accelerate growth of our product revenues and build upon our commitment to delivering innovative, patient-centric therapies,” said Michael Castagna, CEO of MannKind.The company has now submitted a supplementary application to the FDA for approval of Afrezza in the pediatric population aged four to 17 years. The agency is expected to make a decision on the application by May 29, 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MNKD">MNKD stock</a> fell from ‘bullish’ to ‘bearish’ territory over the past 24 hours, while message volume fell from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:624/61;" src="data:image/png;base64,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" width="624" height="61" alt="MNKD's Sentiment Meter and Message Volume as of 11:00 a.m. ET on Nov. 5, 2025 | Source: Stocktwits"><figcaption>MNKD's Sentiment Meter and Message Volume as of 11:00 a.m. ET on Nov. 5, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that Wednesday’s gain in stock price might not last.<stembedurl>https://stocktwits.com/nomalarkey/message/635009498</stembedurl>Another sounded optimistic about the stock’s prospects.<stembedurl>https://stocktwits.com/6Figs/message/635008031</stembedurl>MNKD stock is down 8% this year and approximately 18% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-executives-including-cfo-rally-for-musk-s-one-trillion-pay-package/cL2qZJZREGA">Tesla Executives Including CFO Rally For Musk’s $1T Pay Package</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mannkind Corp and the company's inhalable insulin product. Company employee demonstrating how the device is used. (Photo by Lawrence K. Ho/Los Angeles Times via Getty Images)

MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters

The company has now also submitted a supplementary application to the FDA for approval of Afrezza in the pediatric population aged 4-17 years.

<ul class="summary-bullets"><li>In Q3, Ibsrela saw highest demand since launch and recorded revenue of $78.2 million, marking a growth of 92%.</li><li>Ardelyx’s net loss in the quarter, however, was $1 million, compared to net loss of $0.8 million reported in the corresponding quarter of 2024.</li><li>The company is now looking forward to filing an investigational new drug submission to the FDA for its early-stage candidate RDX10531 in 2026.&nbsp; &nbsp;</li></ul>Ardelyx shares soared 22% in Friday’s premarket session after the company raised guidance for its irritable bowel syndrome drug Ibsrela, which saw the highest demand in the third quarter (Q3).“IBSRELA continues to outperform and is the foundation of our portfolio and the main engine for Ardelyx's future growth,” CEO Mike Raab said on the company’s earnings call on Thursday.“Demand growth is broad-based and demonstrates how vital this therapy is for patients. We expect this momentum to continue through Q4 and beyond, and as a result, we are raising our guidance,” he added.<h2 class="st-heading-2">Revised Guidance, Q3 Fineprint</h2>The company now <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-reports-third-quarter-2025-financial-results-and">expects </a>revenue to be between $270 million and $ 275 million from Ibsrela for the full year. In the third quarter, the drug generated revenue of $78.2 million, marking a growth of 92%, and accounting for 74% of the company’s total product revenue for the period.U.S. revenue for Xphozah, used to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis, was $27.4 million in Q3 despite dynamic market situations, the company said. Ardelyx now expects continued growth in the fourth quarter for the drug.Total revenue in the quarter, including product and licensing revenue, came in at $110.3 million, above an analyst estimate of $100.54 million. Net loss in the quarter was $1 million, slightly wider than the $0.8 million net loss reported in the corresponding quarter of 2024.<h2 class="st-heading-2">Future Pipeline</h2>In the third quarter, Ardelyx began developing RDX10531, an early-stage drug candidate. The company is now looking forward to filing an Investigational New Drug submission with the U.S. Food and Drug Administration for the candidate in 2026, to initiate trials in humans.“We are committed to building a broad, sustainable pipeline, capitalizing first on an internal asset while, in parallel, we explore external opportunities,” Raab said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARDX">ARDX stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:623/57;" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAm8AAAA5CAYAAABgfsxLAAAQAElEQVR4Aex9C1RUV5b2d3lYxUMoUJAyOqFao2JMOhrTY+hOJ9J//EdoexkwD2WFLEWdKMa1Ek16ppfTq1fadK9Oa7pnEjRLxXScwWjiI2uImNERx3YCmo7SGW0wPqawJakKIIUIVJUUMGffelBV1ptXAbvWPXXP3Wefffb57q2Pfc659xLRwx9GgBFgBBgBRoARYAQYgWGDQAT4wwgwAowAI8AIhIQAV2IEGIGhQMBn8HbnTidaWm6joaEZ33zTyIkx4GuAr4EhuQaIg4iLiJP6myjJJtmmNpjnmOf5GuBrYKiuAeIg4iLiJH885zV4IwMGQyuioqKQlJQAtXo8Jk5M4cQYhOU1wNfmyP1tEvcQBxEXEScRN/kjtkDLyRbZJNvUBrXF19LIvZb43PK5DddrgLiHOIi4iDiJuMkXj0V4Krx585YsTk1NRnx8DKKjoyBJkizjL0aAEWAEBhMBSZJkDiIuIk6itu0cRflQk90G2STbzHOhIsn1GIFhj8CQd0CSguO5u4I3ivYiIyOgUo3lgG3ITyc7wAgwAs4ISJIkcxNxFHGVc1kweapLNpjngkGNdRkBRmAwEJAk/zznErzROqvZfAeJifGD4R+3wQgwAoxASAgQRxFXEWcFa4DqUF2yEWzdAdfnBhgBRoARsCFAHEVcRZxlEzl2LsFbR4cJcXGxPOPmgIczjAAjEI4ISJIkcxVxVrD+UR3muWBRY31GgBEYbAQkyTvPuQRvFN0pFNGD7R+3F34IsEeMQNgjQFxFnBWso1SH6gZbj/UZAUaAERhsBIiriLPc23UJ3iyWLkRFRbrr8DEjwAgwAmGHAHEVcVawjlEdqhtsPdZnBBiBQBFgvf5CgLiKOMvdnkvwRoWSxE+VEg6cGAFGILwRkKTQuUqSQq8b3qiwd4wAIzCSEJAkz1x1V/A2kjrNfWEEGIHRjQD3nhFgBBiBkYgAB28j8axynxgBRoARYAQYAUZgxCIQ3sFbqx661pGAPfeBEWAEGIFwR6AelYfP4Ea4u8n+MQKMAPoevHXrUblvJ95+m9J27D58Ac3dISLbeAalRy47Kl89fRgHTl9zHA9U5tKR/ahsHCjrbJcRYASGOwINn+3Htp3HcMmZ266fwu53w5M7LF+WYVtZjQvst84ewPsn9S4y1wMDvqnTo9lVyEfhgAD7wAi4IdDn4E33X8dwUbUAL720SqTVeHJmLBShWm02oNlodrg4NWcNXsqZ4jgemEwrmm+aYbIMjHW2ygiEOwI9PYBR/O5u3+6AwXAbTU0taGhohl5/Ezpdo0hN+Pbbm2hsNID+pdStW21oazPC0+Pr4d7XUP3rMpsR1VOPixd6LVz6n+swwRyW3BE1TY3Euuu45HC3FX/5yoBUTZpDwhlGYDQhMNJ4LtQwy3HOTXd6gy0gEpOnT0GcrbT96ins27kT27btxG4xo9ZOcppdK/sCF4/swbZ33sHvaDRrFAUkP34Nlq//G9tso1ka7ZZ+Zp0So3zZZxfw8Xtihu+fd6K0sh43Th/A7m3Cxrtl+FI2Lux0G/DlYWH7XdHujgOo/FrIxEazaxV//kz25225vnUESvJzBkFsh4W+8FGo8sYIjHgEOjstaG1tlwOyO3fu4Nat27h9u10EcSY5KKNH07u7u0GE1yO+urq60dlpAb3tu73dKOq2gfYUzBnE74eCP9IbycBFJSSg+coFaxe7L+NSQwJSY62H8nf7NVTs2y34S3BJyVFcsnGS7rMD2CE4cNu7u7HvdD1onOhJ1vzno3if+PKd7Xh7zyno7LN8X5+ReWsbcZqc9ltXCry0J/sSMw2axHpo6+QjEZ1fhvbWJGjSxbGdI8mnbXtQVtshhG4b8fG/nUGDTUz8W9pPXGwzyTtGYMARGMk81+fgTfPY41D/tUwEYR+j4kKjTEzyGWk+gwPHDMhYtgpr167A9+6cQsVXosRihrnuKzQ/mI+169ZhYeo1nD3fCqTMQ/5jk4B7foC1Lz6LzBSARrtmc5eoZM3XXTfjhy+IGb7nZ8Jytgxnxy7AirXrsGiyHuc+twZ5l44cwLnEBcKGaPcpNa6cOINbwoLZ2IhL15OwsNBW/1y1PCqdkbMI98cn4P6nhH7ONKHJGyMwchGgoKy5uVUO2traOmwBWScUijFBd3rMmDFyMEeBGwVwNFvXLgI7EesFbWtYVEidAo3hK5yjweZXgsPumYTkTrvnBlQerEBzxnMy96yeZ0FFBd0CUoOzXwB/+6LglxdXYMm8SYiCJxmgUM/GYsFPa9etwZOJNThWJXgRjaj4tAbjFlD9VVgwWYHJ/+9ZwY/e2rP7k4D7p8TixuV6WWC+cA3N6VMwQxxdOrIP5wR3rl0rbL4wG+0nDqPSfa2UeFrMNlrZ18q//cXFwgXeGIEBRWA08FyfgzfETcOi1Wvwwg9T0HxmP962zaSZr15HqxipWr6qxrnz/wPzGAUav7bOdiF2Eu6bHAn6JI6NE0Gah5EfFbqluDRBluRxcgLioMZ9DyXIGnExCqCHaOY6tF9HIlmpE22Kdm9YoGjTow7WT2r6TCTa6xM5WcX8zQiMeAS6urrEkmirvBxqMjnPlkMOwEIJ3iLot+SEHM3O0ZIqBXEU0DkVjZCsGrOmdODKXzpw6bIBkzPEYNPeM+M1MbOVgMQuEdydr8aXxigoG3TQIR2aeww4e+AULurMiIqG+HiSAXETUtBVV42KI2X4cxMFTMSLxGsKKMaKamKLjDSjtVmcP6/tCSXblpiRDsWNa8IH4NJfm5E+jQanxJFxSP+ubfk07gE8dG8rtFeFTVu9QHZ95eJA2mAdRiBYBEYTz7nRb7BQ2fVFwDT9+1iyagUy4y7j3AUzTGJZxl4q79UP4HvTk+TswH2ZYel0tp6A++bNxmRnEecZgVGGAC2Hfvtts1gS9fwHmpYWoqOjgkIlKipSLK/SAuDd1ewESvfO0Qj4bo3hK1E/NAXmy8dw8da9mHWvUz/Mlt5VBxJHpOG786YjGbH47hIx4zY3Dtpje7DtcA3MHmViJu3fduPoVQXue2wBHtfEkRWR0vC3sxX48uB+fHx4P042TEPWXIWIuL21J6rYt+QpgvvqoW2+gCv6dNw3nQqIIyOhjKZ8b7J0er42ejWCzVE7znXCi4udPeP8yEBgtPFcH4O3Dlw6/QVuuARMEEswCiROUkPRYUHyQ7Px8ByRxH7WPQr4/XT71fChcC8mpnSgPWq6tU253XsFgfqoIhdZ0NWndmUj/MUIhBUCFDjRQwb0III/xyjgiowMnA4UYpmV7n/zZffOnU55eZaWUn3pDauy5JnQdNajXfMg1M6OqyZhoqIdlmTBdcQ7lDLSoECXGFBGIvk7c7HohXlI/es1XPEoq8c3hjQ8vGAmJico0G60B1Ot+LKmCw/nLcb8Hy3GioLHoabT5LU9Z6fSkKHpgrbiGhomW5dMgXsFRxqgvdxhVey+Dq1OgYmTrKsYVqH4niDCzjYDGmRe7EBDU7sQBrNRO6FwcTBtsC4jAIxWniMa6MP5j0XqWB2OvrvdepPuO+/j3JjvI+u7wuS9WVh0vwFHt+1BqRgxyo/U3xRyX9u0adA0nMLb74oRKN0f50vXY5kCDy9agIQv38e2PR/jwJ7d2HHkMuw06LEKBMF9JwoXD+3Etn1n+DF5zyCxdEAQGDijFDg1NRnke9oCacVsDu6+t+joaJk0/dmmhxhoKbWl5bY/1WFSnoQfPleAJfOS3PydhCdzZqL50+3YvbcMpSU7UXrGADRW48B7u/H+AZKdQfuDj2CWJxkmQZOix/GS/Sh9vxS1xlib/QRMTm3H2b2CR0Xa9t5+lJ2+hnah77E9uH7UUyah/YYOEwW3WkucObIUu7cdQ/P92XhSnkVMQmJcPc6d1gMR0zDrb3SooIca3j2Mhrhka/WAv53bCZSLAzbOioyAjMBo5rk+Bm8QM2uLsPqlNShc9ixe+Ps1WLtktmOmS/39Z7F27bP4MY0YxT5znMBb/ThWFIrRo8jSps4qwIos2/0XMTOxeN0arF6+AgvFFL9zmXMeeABLXl4MihHvskH34K0SNvKysHDpCqxeNE2MfiGWLtZhib2Ce/35BXh5dQFWPzfP4TvZ5cQIDEcE6H4zWrLs7u4J2H2z+Y6YMQ/8oYWeHnlKJmD7HR0m+TUjPcP0aQYX/lEkIE5edkxDVmEBsuxTcPfMQ/6La5D/48exZPkq5GeKAC9lLp5bvQL5Cx/H4oJVeGF+GuBJhiQ8/NwqrH56IZY8n49FS/KtvNh9GX/+ehIW08MFL4ryZ+ZBefkznNUJ6D21J8QumxhEr355DRZnOEkdHLkI+cJu/veFT3KxCEBXrkGBfKzArKcEnxc8i8LV+SIwfdbqj9BzwcKdS5353NFOlgsXCxO8MQJ9RmC081wEIdgfSZFgJzQ3axEKJIplAAT8iRR/RNDnT1ScF3+8WVYoENxdP94MsZwRGDoEaImSnvwM1gN62EChiEZiYjySkhIwfrwKqanJUKvHy4nyJKMylWosaJk12DYoQKRXiwzXAC7Q/hIXKiJctT3xkSfZXXXN7WIJtQPNLfTgAtDVqkNDVxJSVb3276rTW+QzR+27+4mISEQ5+R6qbeeGqR1rsOss5TwjEDoCzHOA0880dCC5JiPACAw9AjS7RUuUwXgSG6uUAzUK0iIiIhAXF4OYGAXGjIkGPZQgSRIkSZLzJKMyqpOQEI+UlCTEx8ciMjIi4CZpmYMCuIArjHbFmNlYkncvGk6V4+PDZTj6ZZRYtl2EWTFhBQw7wwgMGgLMc1aoA2ddqz5/MwKMQBgiQDftBhO40QMHEyYkQyVm0SgoC6VL0dFRSEiIw4QJ48Q+Xg7yEMCHAjh6QXAAqqwiEIiaMBsLn1qExZT+bi4mJwghb4zAKESAea73pHPw1osF54Y7AqPUf1qGbG6+Bdr7gyBCzK4lJY3FuHGJYsYs0p96wOXx8TFimTUJFBQGUoleEEzLqIHosg4jwAgwAsRvzHO910FEb5ZzjAAjMBwRoBk3GpH68z0qKlJe6oyJUfpTDak8MjJSDgpp6TUQAwbDbdC9doHosg4jwAiMbgQGg+cCQThceI6Dt0DOFuswAmGKQHd3N0ymO369o6VRukctMnLgf/L00EMgARz5bjSa/PrOCowAIzC6ESCuYJ5zvQYGnsld2+MjRoAR6EcEaMZtwoRk+UEDb2YpcKNlUkmSvKn0u9xfABcVFSVm6VTokDpRf6up39sf3gbZe0aAEXBGgHnOGQ1rnoM3Kw78zQgMOwTo31rR+9wo0VOg9DoPCtScO0IzbcnJiQE/TOBct695CuDc74GLiJDk15HEJ8Xi7bNlePzd1/Crk/v72hTXZwQYgRGKAPOc5xPb9+DN1AK9Xu+WWmCyeG4wPKUV2DhZDfUrFcG559b3lrbgqqOuGDmi3ZztWrmidnsO1JNzUCz/J30TyterkTR5I6p8YhmiLj8tBgAAEABJREFU73KLvr+4NLwRsP/bKzu50f/2o/ewJScnOB5GoGMKmIaqJ+QL3WtH7dNSakpqMj7VnkfWjn/AtqpPYLZ04j++Og9ts55Uwje5/datnDe6eK7F5Hx6TGgh3rcLrxYjMykJOe8FcB7deM/ZKucZAXcEmOfcEbEe9z14O14EtVoEPi4p0xaAWBvx9F1eIEEqKPdUNAQyE3T1IgBtcmEn/3649T1prOjT5DyUXPJfVdawmKAV7WrtQV+bFvp6bW/gK9wRm6zq/StE370b5JJhgAAtI5hMZhdPjUYzGhqa0dnZhZQUlViWTJTf1+aiNMgHkiQhWcz8paYmQdvegKf+dTNePVKChrZbDk960IPtZ8KFCxxuuWbcfutWzhtdPFd03BmSChQR56+v6BWa/LOVrOzOe7KQv0YgAn3uEvOcdwj7HrzZbOfu0UGns6dKFKXbCjzu9CJY8lgwLIWOvl/YheymQ1i5tgT6PvdEiewdOhhvbMGjUX025mLgF7/4BZ555hkXGR8MLwToRZWePKbH6WkGrrHREHTg1t7ejvXr18tLrJIkITMzE/X19XIzv/nNbxxySRKDFFsiuazg44tm3nZ9cQy5InC7qJenle/SLqs9i45O12D0LqUwEDh+6zLXjS6e8wn/1CJUGo04sjzNp1qohcxZoSI3vOv1N8+1tbXhiSeeuIvL4uLicO7cORCfSVIvv0mSNU9yf0gONs/1W/CmVKUhLc2eVFBaqrDpETXUC4ohLwqK440Zasx5bS9+nz0b604C+CBfLBOqYV02tC7/rSurxdbHYgS4M7H1qtBpKsfG2XRMIArdnbVCSJtVf+XOCmzNVgt9Ua7OEbNeeuwtsB1HZ2Kr8yyYV1tkz560KM4Sfuc6BWBth7CSljd36u1KLntH32flIXe+KLrdAqPYAVYfrf0jgbAtfFVn2zAhkY9U8YrwQyybWse2Laj6eSZibBeT5D7DZ6lGsbAtSQIH9367tUFEOHPmTA7g3HAZTofeSM3eByISSZLshwHt9+3bhz/84Q84deqUfBtEZGQk3nzzTbnuT37yE3z00UeOtGLFCnnGPS8vTy739zUrTf7P517VaPn0P69Uey3vU0E/Vnb81mWuG1085xNG96VQSy1Kcm08LK7DJMGfapF6uVBYaxTcniHZuHslyluEzMv2CzHgZM7yAs4IFvc3zymVStC1ZOeyvXv34oEHHkBOTg4efPBBDCee67fgTXv6EA59ZE0Vl0yA8lFsej0HpuPrsO6DFui3bxCB1EwUrc/F/395E3JpgDavEMVvFWPDfLW4/ExiNk6P4p/MRLF6M0o/LEV+erUIAHOwtS0fBy/oULM7E5WrM7HxDMTHql+yOg/lc7fi4Ju5UOnLsTJDg83KTTi4pwizLVXYKIJF4Q0ggptNj+R4sSXMOTYN8p7SQH+4BAetkw4wlZWgpF6D7IXktEPRkbH3vfiVbGw8qkLuK/nQyKVWHx3LokJmuqGH/obskTjyvZmahG69DrL21RIU/rIKmf9SI2Y4a3BkfRY0zu58sAWHCAd7v/3M/tEFzGToG/9wLaX/UECPzvvyLz4+zlexx7KmpiZMnz5dJrMJEyZg3rx5uHbtGkxiOSwjIwNLliyR09y5c/HHP/5RDuymTp3q0Za78Afp92NWWrq72OX4k9rPXY7D8cD+WyeuG608R30/9FGFdVBuP0kW11tAagX3rzw8E+9cMcJ45R3MqdcjaeFmG9dbK9X+dita1h+0cXcJ8n5eZS3w8s2c5QWYESoeCJ6jp9yfeOIJmceIzyIiItDa2opf/epXiI6OxnDiuX4L3qp+m4e8Z6xpXZlOvpyUC7egZKkS5T/LQvZrVch4cxcKJymR8WQ25owXKpos5D6di6wZSnFg2+a9g8oPN2DZ07ORdrwYb9QBy17fjEyhn7SwCIXpLSg/Lc/lWSs8X4oTry9D7qubsXGGEM3ajCM7ipD7/AbkzxLHWrGUK3YIxBbpiZS2fB1yUYXSwzTTZhJBaTkwvxB5k0Shh61qZxGKXinC5u1VaIkSfanXwsMgEv3x0dVqYYjPQParRchSOVm04/D8FmxcJOSNLTCKna+NydAXOuFb5u99R5GREVAoooPuwIIFC0DB2k9/+lNcvHgRp0+fxtKlS0GjVbsxWpb9/e9/j3vuuQeLFy+2iwPaP/vgYz71Prteg+6eHp86Q104qnnOiePzntkKX6GWtk5w9KxsZE9VQjlV7AUX14ohrTPXZ7x5ArvW5Aru3oSiNMDUYvB7epmz/EI0YhQGiufsADU0NOCXv/wl1qxZA/dB6HDguQh7R/q6X/bvPfK/56FO17xqnXcCxCzU+iKo6qpRbSnEOy/b5fD+uU8D8TuWy7UXK+X93mVi+ZBujlX/CFtFMCcL7/oSJBF1l9AhCMpW/DIUrVGiakcptJYKHDkMZC3NcfjlMGrLLKP7/W6IINHYg5rXk3DotXxsuWgr7K/d1A04uCMXhp05mDlWglos69Z6fApVCZUK/BnBCHR2ejzxjh7Hxiod+WAys2bNwvLly7Fz50559m3MmDHycoKzjbq6Ohw4cACrVq1CfHy8c5Hf/I8zvodIyTvlGDvv4NpN68DPr7EhUhjVPOfE8T09R7DMxzmY81gWcLEExSe10J4sRongw9z5mV5qqJAkBudeClnsQGB0ZQaK5+woVlRUoLm5GU8//bRd5NgPB57zzqSObvQlo0fJz7bCND8LGZYSvBHIY+ROzWlmzBZHShRV9AaGrsGhKA5wC9ZW1rJCKAX5HHqvHIeQjcKlaQG1lCFISykWFLTaXnWDoX/m4TJWHYTOaETNh8sQc3glcl6v7W0khByNYmtqavDhhx+GUJurDBUCnZ2dPpt2f7eaT2VbIf2u3njjDfmm3Zs3b+LYsWMgAisoKIBRXHM2NVRWVsrHc+bMsYsC3icq4zBzwt/41P/Lt9d9lodn4ejjOX/nIe3pIuQqDTi0NhOZa6uRubsGpUtDG1Q4t8Wc5YzGyM4PBM/ZEbNYLPIgdPbs2Zg4caJd7NgPB57rt+DN+V4Quieiuh5o+aAQK09mYPOOEyh5SYWK1YXYa49j6Hf8USn21unRYn9VhgM6W2Z+PgpVJhSvXolDF/XQ67Wodr/XwqbqdxeILVML7K8twg+KsCG9FpvWl8C0KB+5PiYZTC02344WY+XyYpjEomvOfPIoCUmin/qyUlTUaVHx83xsFCNQKnFJIrhzfi+eocXkUiwfXCrBxt9WQG9SIoOCYSE0WjzoCXkgG5NgICiFnw79L9Dubt9Li9HRPqagvXSJ7vv49NNPsXDhQiQnJ+PJJ5/Er3/9azlYqxOzbfZqJ0+eBD2YlJKSYhcFtff34MKlxhtB2Rts5dHMc8Fgrd25CYce2ogjf9JBV3sCu5ZnQFBhMCbu0mXOuguSESsYKJ6zA0YD1OrqakyZMsXlthB7+XDguX4L3pzvBaF737b89yEUrSiH8vktKJoKPPp6CZYpy5FfsBct0KDw54VIM+1FvkYNjbcbVeOzsatqF7LbSpD3gBpq9XcwZ30xquoQ/MenrSzkL1cBH+Wj6KjddAbWvfIo6Gbt3KW5PonnUIHNt+x1OKgqxMErpVgmB3uPYsObjwIXt+JHmu8g/4tCbHkevZ+puSicC9T+Oh/0ZK3mqULMRi3eeH6r+O5Vo1xLSwtq3/oR1GLJVEpZifIZG1D6Gs1MUmlwKT09HTU84xYcaGGi3d3d7dOTqKhISJLkU8dToUKhwLhx4/DJJ5+A7gWh2bbjx48jNTVVDuaoDr1KhAI5Ctyc74OjskDTjJTJPlWb2lt9lg914WjmuWCw1yzMR8aZjaBbPCRJkq9JSX4bQDBWenWZs3qxGA25geI5O3b0ku3Gxkb53l27zL4fLjzX9+BtUanjXjdaerGn0udyUWrsgXFPtjXwUVmPe/59GUSYBNWiXdAZDdA1GmF4SwQ4YmmytKcHPUIfzp8ZhTiiE3YaxQiu0Yge3UEsSyeFbLjqa7DhQg96LmyAhorFt+uxEHq1pUT2bgOMjQaU0M3+QrV3y0XeIi9jRg99N/xpF3Kn9uprXqpEz23RT4MRuvJCbNjj5uOfjDDoKrFhhmhx6gacJ0yqNiBDHGaTbk+pQAZQzdvQi4Ow1VO7xfbAQrYbDoBcz4GDMOS20R9gXip1A2WYHPojtYiI0H7SFIz97ne/g9lsBj1pGhsbi/Lycrz11lvyMcFDbVP5+PHjPY5WScdfSolL9KnSbPQ2De+z2sAXevitE9eNJp4rdeFGN94R3FUj+Nt6v7MJ5W9tgenVE9DpdNZ0YQse1Zdja5kWcNGlU6excrc791ORLdXV1fHtHTYsRsOOuMZXP0PlObvNO3fugJZOJ02aZBc59tT2cOC50Jje0c0+ZpQqpI1XBmREOT4tYF1/Br3ZUo5XQRklal+tQPFv85C5vgqaf9wE6yyakIe6xYt+qrz1UwlVmmgXto/Sly4g++7Vls0G70YsAt1+lkwjIqSQ+z5t2jR8/vnnMBgMoNeGfPvtt6BlVLvBsWPHyk+g0gML9Mi9XR7MPjl2rE91Q8dtn+XDspB+0+OVAbku/74D1PVn0JutAeM5h0PVKP+gBQZ9CwS5IU3wG2rPi9UEFTJnqR1aQ55hB8IWgYHkOer0I488go6ODuTn59OhSxouPDe0wZsLZOFzoD2+FZv/pRaafzqC86+HtjQZPr1hT0YSAjExCkycmOI10b+i6mt/VSqVvIQqSaEHgt58+N7kafjfn+72mg4X/JO3qizvZwQGjucexeZysQJSlgd1jARJioHmZ3oUHqrFroXKfu4FmxuJCAwGzw0kboPBcxy8eTiDmjVHoLtRgxOvZ0MV5UGBRYxA/yHAlhiBIUFgIHlONX8Lzht6HLfUGK+cwJan0oakn9woIzASEYgYiZ3iPjECjAAjwAgwAowAIzBSEegN3kZqD7lfjAAjwAgwAowAI8AIjCAEOHgbQSeTu8IIMAKMwFAhwO0yAozA4CFwV/BGj78PXvPcEiPACDACoSHQF67qS93QvOVajAAjwAgEj4A3rnIJ3ugFnxZLV/DWuQYjEDYIsCOjBQHiKuKsYPtLdahusPVYnxFgBBiBwUaAuIo4y71dl+BtzJhomM2d7jp8zAgwAoxA2CFAXEWcFaxjVIfqBluP9RkBRmAUIBBmXSSuIs5yd8sleIuNVaK9vUN+vNtdkY8ZAUaAEQgXBGgpgbiKOCtYn6gO1SUbwdZlfUaAEWAEBgsB4ijiKuIs9zZdgjeK7hSKMbh1q81dj48ZAUaAEQgbBIijiKuIs4J1iupQXbIRbN1B1OemGAFGYJQjQBxFXEWc5Q6FS/BGhSrVWHR1daOl5TbPwBEgnBgBRiBsEKCRKHETcRRxVaiOUV2yQbbIZqh2uB4jwAgwAv2NAHEScRNxFHGVJ/t3BW+kNG6c9Z9HNzQ0o63NiM5OCwdyBK9PzoQAAADSSURBVMxoTNxnRmCIESAiIw4iLiJOInfsHEX5UJPdBtkk29QGtRWqPa7HCDACjECoCBD3EAcRFxEnkR07R1HePXkM3kiJor2kpARYLBYYDK3Q6ZrwzTeNnBgDvgb4GhjUa4C4hziIuIg4ibiJOKo/Etkim2Sb2qC2mOeY5/ka6L9rgLEMDEviHuIg4iLiJOImXxznNXijSrTOSgZSU5MxcWIKJ8aArwG+BobkGiAOIi4iTiJu6s9ENsk2tcE8xzzP1wBfA0N1DRAHERcRJ/njuP8DAAD//4yX3j4AAAAGSURBVAMAc5sDD4U8fV8AAAAASUVORK5CYII=" width="623" height="57" alt="ARDX's Sentiment Meter and Message Volume as of 8:50 a.m. ET on Oct. 31, 2025 | Source: Stocktwits"><figcaption>ARDX's Sentiment Meter and Message Volume as of 8:50 a.m. ET on Oct. 31, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sees the stock hitting a per-share price of $7 today.<stembedurl>https://stocktwits.com/badgermobile/message/634454149</stembedurl>Another expressed optimism about the CEO saying on the earnings call that it is open to external business opportunities.<stembedurl>https://stocktwits.com/Dragan7/message/634447443</stembedurl>ARDX stock is down 1% year-to-date and by approximately 15% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-shareholder-gavin-baker-supports-elon-musk-1-trillion-pay-plan/cLGqGXNR3Ul">Atreides’ Gavin Baker Backs Elon Musk’s $1T Tesla Pay Deal Despite Broad Opposition</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ardelyx logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Ardelyx Shares Soar Premarket As CEO Sees Continued Demand For Blockbuster Drug Ibsrela

The company now expects revenue from Ibsrela to be between $270 million and $275 million for the full year.

<ul class="summary-bullets"><li>The company announced the exercise of existing warrants held by an institutional investor.</li><li>The investor will receive new registered warrants to purchase up to 22.4 million shares of its common stock at an exercise price of $2.00 for the exercise of existing warrants.&nbsp;</li><li>The transaction is expected to close on or about October 28, the company said.&nbsp; &nbsp;</li></ul>Shares of SELLAS Life Sciences Group, Inc. (SLS) slumped 6% on Monday after the company announced the exercise of existing warrants held by an institutional investor for $31 million in gross proceeds.The warrants were previously issued in March and August 2024, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-Group-Announces-Exercise-of-Existing-Warrants-Held-by-a-Current-Institutional-Investor-for-31-Million-in-Gross-Proceeds/default.aspx">said</a>. The investor will receive new registered warrants to purchase up to 22.4 million shares of its common stock at an exercise price of $2.00 for the exercise of existing warrants.The new warrants will be exercisable immediately and will expire five years from the date of issuance, the company said.The closing of the translation is expected to occur on or about October 28, it added.Sellas is a late-stage clinical biopharmaceutical company focused on developing novel cancer therapeutics. Its lead product candidate, called GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets a protein present in an array of tumor types.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/SLS"> SLS stock</a> fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user recommended holding the stock, opining that it will now go higher.<stembedurl>https://stocktwits.com/Kevoo/message/633843705</stembedurl>Another dismissed concerns of dilution, terming the warrant exercise a “not that big deal.”<stembedurl>https://stocktwits.com/Risulom/message/633841655</stembedurl> In September, the company <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-stock-in-spotlight-after-institutional-investor-exercises-existing-warrants/chwNYhvRdvv">announced</a> that an institutional investor had exercised the warrants it held to purchase up to 19.69 million shares of the company’s common stock for gross cash proceeds of approximately $23.6 million. The warrants were previously issued in January 2025, the company then said.SLS stock is up by 80% this year and by about 54% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/dyne-therapeutics-stock-soars-after-rival-avidity-biosciences-gets-acquired-by-novartis/cLG0X2XR3u7">Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Why Is SELLAS Life Sciences Stock Falling Today?

Shares of SELLAS Life Sciences Group, Inc. (SLS) slumped 5% on Monday after the company announced the exercise of existing warrants held by an institutional investor for $31 million in gross proceeds.

Why Is SELLAS Life Sciences (SLS) Stock Falling Today?

<ul class="summary-bullets"><li>Intellia said that it has temporarily paused patient dosing and screening for two of its late-stage trials for Nex-z.</li><li>The decision follows a report on October 24 of heightened liver transaminases and increased total bilirubin in a patient who was dosed with Nex-z in a trial.</li><li>The patient is being closely monitored and receiving medical intervention, the company said. &nbsp;</li></ul>Intellia Therapeutics, Inc. (NTLA) on Monday said that it has temporarily paused patient dosing and screening for two of its late-stage trials for Nex-z after a patient was hospitalized.The company has paused dosing in a trial that enrolled patients with transthyretin amyloidosis with cardiomyopathy and another that enrolled patients with polyneuropathy. Transthyretin amyloidosis with cardiomyopathy is a severe and progressive heart failure caused by the buildup of misfolded amyloid fibrils, derived from the transthyretin protein, in the heart muscle. Transthyretin amyloidosis with polyneuropathy, meanwhile, is a progressive, multisystem disease caused by the buildup of abnormal proteins in the body's organs and tissues.&nbsp;<h2 class="st-heading-2">Why The Pause?</h2>The decision follows a report on October 24 of heightened liver transaminases and increased total bilirubin in a patient who was dosed with Nex-z in a trial, raising concerns of drug-induced liver injury. The patient was dosed with Nex-z on September 30.The hospitalized patient is being closely monitored and receiving medical intervention, the company said.<h2 class="st-heading-2">What Are The Company’s Plans?</h2>Meanwhile, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/27/3174462/0/en/Intellia-Therapeutics-Provides-Update-on-MAGNITUDE-Clinical-Trials-of-Nexiguran-Ziclumeran-nex-z.html">said</a> it is consulting with experts, considering potential risk mitigation strategies, and engaging with regulatory authorities.<blockquote>“In line with our commitment to patient safety, we have taken immediate action to temporarily pause enrollment in MAGNITUDE and MAGNITUDE-2 as we investigate this recent event. As we focus on ensuring the health of this patient, we also are engaging with regulatory authorities and other stakeholders globally to develop a strategy to resume enrollment as soon as appropriate.”&nbsp; – John Leonard, CEO, Intellia Therapeutics</blockquote>Nex-z or Nexiguran Ziclumeran is a therapy based on gene editing technology. It is designed to inactivate the TTR gene that encodes the transthyretin protein. As of Monday, more than 700 patients have been enrolled in the two trials in which Intellia has paused dosing, and over 450 have already been dosed with Nex-z.Shares of the company slumped 43% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NTLA">NTLA stock</a> soared from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘high’ levels.NTLA stock has more than doubled this year and gained about 57% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/bbio-stock-soars-after-experimental-drug-shows-improvement-in-inherited-muscle-disorder-in-late-stage-trial/cLG04ksR3Mm">BBIO Stock Soars After Experimental Drug Shows Improvement In Inherited Muscle Disorder In Late-stage Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA. (Photo by: Spencer Grant/GHI/UCG/Universal Images Group via Getty Images)

Why Did NTLA Stock Tumble 43% Pre-Market Today?

Intellia said that it has temporarily paused patient dosing and screening for two of its late-stage trials for Nex-z.

ProShares Trust - ProShares UltraPro Russell2000 3x Shares

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

URTY
ProShares UltraPro Russell2000

Feed

News

Sentiment

Fundamentals

Info

Latest URTY News

URTYProShares UltraPro Russell2000